Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
NuVasive, Inc. $650 Million Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. (“NuVasive”) of $650…
Pfizer Inc. $5 Billion Accelerated Share Repurchase
Davis Polk advised the counterparty in connection with an accelerated share repurchase transaction entered into between the…
Invacare Corporation $130 Million Convertible Senior Notes Offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Invacare…
Quotient Limited Follow-On Offering
Davis Polk advised the sole underwriter in connection with the SEC-registered follow-on public offering of 4,444,445…
BeiGene, Ltd. Initial Public Offering and NASDAQ Listing
Davis Polk advised the joint book-running managers and representatives of the underwriters in the $182.2 million initial…
Editas Medicine, Inc. $108.6 Million Initial Public Offering
Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the …
Novavax, Inc. $300 Million Convertible Senior Notes Offering
Davis Polk acted as special product counsel to the representatives of the initial purchasers in connection with a Rule 144A…
Abbott Acquires Alere
Davis Polk is advising JP Morgan as financial adviser to Alere Inc. in connection with its $5.8 billion acquisition by…
Stryker Acquires Sage Products from Madison Dearborn Partners
Davis Polk is advising JP Morgan as financial adviser to Stryker Corporation in connection with its $2.775 billion…
Biotie acquisition by Acorda
Davis Polk is advising Biotie Therapies Corp. in connection with its combination agreement with Acorda Therapeutics, Inc…